|
|
|
Corporate Profile: CoMentis
| Summary: |
| CoMentis is focused on the development of two technology platforms: (i) aspartic protease inhibitors and (ii) nicotinic acetylcholine receptor (nAChR) agonists and antagonists for the treatment of angiogenesis mediated or cognitive disorders. |
| Address (HQ): |
280 Utah Avenue
Suite 275
South San Francisco, CA 94080 |
| Phone #'s (HQ): |
| Main |
(650) 869-7600 |
| Human
Resources |
not known |
| Investor
Relations |
not known |
| Fax #'s (HQ): |
| Main |
(650) 869-7626 |
| Human
Resources |
not known |
| Investor
Relations |
not known |
| email: |
| Main |
not known |
| Human
Resources |
hr@comentis.com |
| Investor
Relations |
not known |
| Number
of employees: |
| not known |
| Issued United States patents: |
| Issued U.S. patents: 1976-present: patent link. |
| Filed United States patent applications: |
| Filed U.S. patent applications: 2001-present: patent
link. |
| Publications on PubMed: |
| Scientific publications on PubMed with an author from the company: publications
link. |
|
|
|
